EudraCT Number: 2020-005305-54 Sponsor Protocol Number: CPI-006-003 Start Date: 2021-04-29
Sponsor Name: Corvus Pharmaceuticals, Inc.
Full Title: Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospital...
Medical condition: Covid-19 disease
Disease: Version SOC Term Classification Code Term Level
23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2019-004818-34 Sponsor Protocol Number: CTRIAL-IE-19-32 Start Date: 2021-04-23
Sponsor Name: Cancer Trials Ireland
Full Title: DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamid...
Medical condition: Clinically localised prostate cancer defined as very high risk, or with very high risk features.
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
Population Age: Adults, Elderly Gender: Male
Trial protocol: IE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-000567-77 Sponsor Protocol Number: 42847922MDD1016 Start Date: 2021-05-19
Sponsor Name: Janssen-Cilag International NV
Full Title: A Short-term Exploratory Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have ...
Medical condition: Major Depressive Disorder
Disease: Version SOC Term Classification Code Term Level
21.1 100000004873 10081270 Major depressive disorder LLT
Population Age: Adolescents, Under 18 Gender: Male, Female
Trial protocol: Outside EU/EEA
Trial results: (No results available)

EudraCT Number: 2020-004982-37 Sponsor Protocol Number: NBK155/1/2020 Start Date:
Sponsor Name: MEDICAL UNIVERSITY OF GDAŃSK
Full Title: Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrome
Medical condition: NEPHROTIC SYNDROME
Disease: Version SOC Term Classification Code Term Level
21.1 10038359 - Renal and urinary disorders 10029164 Nephrotic syndrome PT
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: PL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2020-004413-13 Sponsor Protocol Number: DIRECT Start Date: 2021-05-18
Sponsor Name: Amsterdam UMC, VU University Medical Center
Full Title: Dual-immunotherapy and short-course medium-dose radiotherapy, followed by surgery for tumor microenvironment modification in early stage NSCLC
Medical condition: early stage non-small cell lung cancer
Disease: Version SOC Term Classification Code Term Level
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2020-005442-42 Sponsor Protocol Number: C4591007 Start Date: 2021-04-28
Sponsor Name: BioNTech SE
Full Title: A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBOCONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A S...
Medical condition: Protection against COVID-19
Disease: Version SOC Term Classification Code Term Level
23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
Trial protocol: FI (Ongoing)
Trial results: (No results available)
EudraCT Number: 2020-000112-29 Sponsor Protocol Number: NL2020.01.11 Start Date: 2021-05-20
Sponsor Name: Leiden University Medical Center
Full Title: [18F]fluoro-PEG-folate PET/CT imaging in patients with epithelial ovarian cancer
Medical condition: Epithelial ovarian cancer (EOC)
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2020-001001-22 Sponsor Protocol Number: D910SC00001 Start Date: 2021-03-30
Sponsor Name: AstraZeneca AB
Full Title: A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advance...
Medical condition: Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Disease: Version SOC Term Classification Code Term Level
21.0 100000004864 10015366 Esophageal carcinoma LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Ongoing) PL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2019-002597-32 Sponsor Protocol Number: AGO/2019/003 Start Date: 2020-03-16
Sponsor Name: University Hospital Ghent
Full Title: Dynamics and tracer distribution of Tilmanocept using combined subareolar and peritumoral injection technique for scintigraphic sentinel lymph node detection in early stage breast cancer.
Medical condition: Early stage breast cancer (T1, T2)
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
Population Age: Adults, Elderly Gender: Female
Trial protocol: BE (Completed)
Trial results: (No results available)

EudraCT Number: 2020-004407-13 Sponsor Protocol Number: INCMOR0208-301 Start Date: 2021-05-20
Sponsor Name: Incyte Corporation
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addit...
Medical condition: follicular lymphoma (FL) and marginal zone lymphoma (MZL)
Disease: Version SOC Term Classification Code Term Level
20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10080213 In situ follicular lymphoma LLT
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: CZ (Ongoing)
Trial results: (No results available)